Revance Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-10.52	-30.66	-23.88	-	-
Depreciation & Amortization	0.38	0.4	1.25	-	-
Other Operating Activities	4.2	18.06	3.2	-	-
Change in Other Net Operating Assets	-2.48	3.04	16.62	-	-
Operating Cash Flow	-8.43	-9.16	-2.81	-	-
Other Investing Activities	-0.13	-0.75	-14.25	-	-
Investing Cash Flow	-0.13	-0.75	-14.25	-	-
Other Financing Activities	9.83	10.99	10.83	-	-
Financing Cash Flow	9.83	10.99	10.83	-	-
Miscellaneous Cash Flow Adjustments	0	-	-	-	-
Net Cash Flow	1.27	1.08	-6.23	-	-
Levered Free Cash Flow	-7.22	-10.03	10.1	-	-
Unlevered Free Cash Flow	-7.16	-9.86	11.81	-	-
Change in Net Working Capital	2.48	2.57	-23.63	-1.78	-

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.